Background and Introduction: Cardiac imaging is crucial for diagnosing heart disorders. Methods like X-rays, ultrasounds, CT scans, and MRIs provide detailed anatomical and functional heart images. AI can enhance these imaging techniques with its advanced learning capabilities. Method: In this scoping review, following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) Guidelines, we searched PubMed, Scopus, Web of Science, and Google Scholar using related keywords on 16 April 2024. From 3679 articles, we first screened titles and abstracts based on the initial inclusion criteria and then screened the full texts. The authors made the final selections collaboratively. Result: The PRISMA chart shows that 3516 articles were initially selected for evaluation after removing duplicates. Upon reviewing titles, abstracts, and quality, 24 articles were deemed eligible for the review. The findings indicate that AI enhances image quality, speeds up imaging processes, and reduces radiation exposure with sensitivity and specificity comparable to or exceeding those of qualified radiologists or cardiologists. Further research is needed to assess AI’s applicability in various types of cardiac imaging, especially in rural hospitals where access to medical doctors is limited. Conclusions: AI improves image quality, reduces human errors and radiation exposure, and can predict cardiac events with acceptable sensitivity and specificity.

Acute myeloid leukemia (AML) is caused by a defective precursor leading to malignant clonal expansion, often with FMS-like tyrosine kinase-3 receptor (FLT3) mutations, particularly internal tandem duplication (ITD), which has a poor prognosis. Quizartinib, a second-generation FLT3 inhibitor, has FDA approval for relapsed/refractory AML with FLT3/ITD mutation. It has shown promise in clinical studies since 2013 due to its excellent oral absorption and potent activity on FLT3. This review explores Quizartinib's mechanism of action, efficacy in monotherapy or combination with chemotherapy, drug interactions, adverse events, resistance mechanisms and future research directions.

Background. Periodontitis (PD) is a chronic inflammatory disease of the oral cavity. PD can adversely affect glycemic control and cause macro- and micro-vascular diseases in diabetic patients. This article aims to systematically review the association between periodontitis and micro- and macro-vascular complications of diabetes. Methods. This review was conducted under the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). A thorough search of the Scopus and PubMed databases was performed up to 2022. English articles were included. Results. In this study, seven studies with 29,679 participants investigated the relationship between periodontitis and micro- and macro-vascular complications. There were two cohort studies, six cross-sectional studies, and one case‒control study. Follow-up durations ranged from 6 months to 11.64 years. The reports were published between 2002 and 2022. There was a relationship between periodontitis and the microvascular complications of diabetes in four studies. One study found no significant association between periodontitis and the microvascular complications of diabetes. The correlation between coronary heart disease (CHD) and periodontal disease was confirmed by one study. Furthermore, another study found that periodontitis increased the risk of cerebral and myocardial infarctions. Conclusion. The present study demonstrated that diabetes mellitus (DM) patients with periodontitis are at an increased risk of macro- and micro-vascular complications, particularly myocardial and cerebral infarctions.

In contemporary medicine, cancers are recognized as significant concerns warranting attention. Over time, scientific advancements have assisted physicians worldwide in exploring novel approaches. Among these potential solutions are calcium channel blockers (CCBs), which hold considerable importance and find extensive application across various medical conditions. CCBs, classified as dihydropyridines and non-dihydropyridines, have been widely utilized in the management of diverse cancer types. Given the diverse facets of dihydropyridine CCBs, our objective was to comprehensively gather and summarize pertinent data regarding the impact of this medication class on different cancer types.